Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Sequenom appoints new CEO amid diversification

Sequenom is riding the waves of change, appointing a new CEO days after the company struck a deal with UnitedHealthcare to offer its carrier screening tests to the insurer's 43 million covered lives.

Sequenom appoints new CEO amid diversification

Sequenom is riding the waves of change, appointing a new CEO days after the company struck a deal with UnitedHealthcare to offer its carrier screening tests to the insurer's 43 million covered lives.

Bayer sets up triumvirate of managers to run slimmed-down operation

Change is coming for Bayer--and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment--and they involve three operational arms, each headed up by a company vet.

President Obama nominates Califf as next FDA commissioner

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

M&A-minded AbbVie snaps up JPMorgan's dealmaking hotshot

AbbVie could use some M&A to help it diversify beyond best-seller Humira, a popular biosimilar target. And that's something its newest hire knows a thing or two about.

Lehmann leaves GSK to head up immuno-oncology at Celyad

Frédéric Lehmann has joined the ranks of R&D executives to swap life at a Big Pharma for a starring role at a biotech. The move sees Lehmann walk away from a 12-year stint at GlaxoSmithKline to take charge of the burgeoning immuno-oncology operation at Celyad.

Merck KGaA reworks healthcare exec team with new COO, CMO

Merck KGaA has been working to turn itself around for years now, with consolidations, layoffs, reorgs and M&A all part of that effort. Now, the German company is rejigging top management in its healthcare business again.

St. Jude announces incoming CEO's new C-suite

St. Jude Medical announced the new executive team that will serve under incoming CEO Michael Rousseau, beginning Jan. 1, 2016.

UPDATED: Melinta's CEO steps down amid a big Phase III push

Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech raised $67 million in equity financing.

Michael Rousseau to succeed Daniel Starks as St. Jude CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...
'